azd2820
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2011 (NCT01332214)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Melanocortin receptor 4PARTIAL AGONIST
MC4R partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd2820
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01469923 | Phase 1 | Mar 1, 2012 | AstraZeneca |
| NCT01332214 | Phase 1 | May 1, 2011 | AstraZeneca, IQVIA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 1 | 2011 |
| IQVIA | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1